Key result
NLRP3 inflammasome inhibitors like colchicine show promise for reducing post-procedure AF recurrence.
Why the study?
Preclinical evidence suggests the NLRP3 inflammasome may play a prominent role in the pathogenesis of AF, suggesting therapies reducing ASCVD events might also benefit AF.
Do colchicine and other anti-inflammatory agents targeting the NLRP3 inflammasome prevent the onset or recurrence of atrial fibrillation?
Do colchicine and other anti-inflammatory agents targeting the NLRP3 inflammasome prevent the onset or recurrence of atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Preclinical and clinical evidence implicates the NLRP3 inflammasome in atrial fibrillation pathogenesis, positioning colchicine as a promising anti-inflammatory agent for reducing AF recurrence after ablation or cardiac surgery pending further randomized trials.
Increasing evidence suggests that the "NACHT-LRR and PYD domain-containing protein 3" (NLRP3) inflammasome plays an important role in atherosclerotic cardiovascular disease (ASCVD). Recent preclinical evidence has suggested that the NLRP3 inflammasome may play a prominent role in the pathogenesis of atrial fibrillation (AF). As such, the therapies that have shown efficacy in reducing ASCVD events may also prove beneficial in AF. In this article, we review the findings that implicate the NLRP3 inflammasome in the pathogenesis of AF, discuss existing evidence behind the use of anti-inflammatory agents for AF, and discuss the future role that colchicine and other anti-inflammatory agents may play in the prevention and treatment of AF.
No takes yet. Share an insight, caveat, or question.
Varghese et al. (2021) conducted a review in Atrial fibrillation. Colchicine and other anti-inflammatory therapies (canakinumab, corticosteroids) vs. Placebo or standard care was evaluated on Prevention and recurrence of atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: